Early Phase Study Aims to Improve OS in HER2+ Breast Leptomeningeal Disease
Kamran A. Ahmed, MD, gives an overview of the phase 1/2 study of radiation therapy followed by intrathecal trastuzumab and pertuzumab in the management of HER2-positive breast leptomeningeal disease.
Kamran A. Ahmed, MD, a radiation oncologist at the Moffitt Cancer Center, gives an overview of the phase 1/2 study of radiation therapy followed by intrathecal trastuzumab (Herceptin) and pertuzumab (Perjeta) in the management of HER2-positive breast leptomeningeal disease.
According to Ahmed, patients with HER2-positive leptomeningeal disease have a poor prognosis and high unmet clinical need. On its own, radiotherapy remains an important treatment strategy for leptomeningeal disease and trastuzumab is an important treatment for HER2-positive breast cancer. According to Ahmed, there is a strong clinical rationale for their combination for the treatment of HER2-positive breast leptomeningeal disease.
The phase 1/2 study has a single arm. After treatment is initiated, patients will receive either 10mg, 20mg, 40mg, or 80mg of pertuzumab. The trastuzumab dose will remain stable. In order to participate, patients must have a life expectancy of at least 8 weeks.
FDA Grants Clearance for Phase 1 Trial of BL-M17D1 in Solid Tumors
November 11th 2024Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel antibody-drug conjugate BL-M17D1 in patients with advanced or metastatic solid tumors.
Read More
T-DXd Use in HER2+ Breast Cancer Influenced by Site of Metastases and AE Monitoring
October 21st 2024During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO discussed recent updates from the DestinyBreast03 trial and other key data on treatment for HER2+ breast cancer in the first article of a 2-part series.
Read More
Wei Assesses Role of TROP2 and HER2 Status in Treatment With Sacituzumab for ER+ mBC
September 26th 2024During an in-person Community Case Forum in partnership with the Rocky Mountain Oncology Society, Mei Wei, MD, discussed data from the TROPiCS-02 trial of sacituzumab govitecan in patients with metastatic breast cancer.
Read More
